Bulk Pharmaceutical API Sources for NUCYNTA ER

Bulk Pharmaceutical API Sources for NUCYNTA ER

Vendor	Vendor Homepage	Vendor Sku	API Url
MedChemexpress MCE		HY-70042A
AbaChemScene		CS-0879
ChemShuttle		101151
Sigma-Aldrich		T-058_CERILLIAN
Clearsynth		CS-O-11752

Bulk Active Pharmaceutical Ingredient (API) Sources for Nucynta ER

Last updated: July 31, 2025

Introduction

Nucynta ER (tapentadol extended-release) is a prescription opioid analgesic used for managing moderate to severe chronic pain. As a Schedule II controlled substance, its manufacturing and distribution are highly regulated. The core component of Nucynta ER, tapentadol, is a synthetic opioid that acts centrally to relieve pain. Securing reliable bulk API sources—primarily tapentadol—is vital for pharmaceutical manufacturers aiming to produce Nucynta ER with strict adherence to quality standards, regulatory compliance, and supply chain stability.

This report provides a comprehensive analysis of potential bulk API suppliers for tapentadol, highlighting key considerations such as regulatory status, manufacturing capabilities, quality assurance, geographic distribution, and market trends.

---

Regulatory Considerations and Compliance

Given the stringent regulatory landscape surrounding opioids, especially in the United States, API suppliers must meet rigorous standards set by agencies such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and other global regulatory bodies. Suppliers should possess current Good Manufacturing Practice (cGMP) certifications, with full transparency of their quality management systems.

The U.S. Drug Enforcement Administration (DEA) also enforces tight controls over opioid raw materials, requiring suppliers to have appropriate licensing, secure facilities, and audit histories demonstrating compliance. These factors are critical in vetting API sources, ensuring that the supplier’s processes align with legal and quality mandates.

---

Major Global API Manufacturers of Tapentadol

1. Mitsubishi Tanabe Pharma Corporation (Japan)

   • Mitsubishi Tanabe is recognized for its robust pharmaceutical manufacturing infrastructure, including complex synthetic APIs like tapentadol. They have established cGMP-compliant facilities catering to global markets, including the U.S. and Europe.
   • Notably, their reputation for innovation and stringent quality controls positions them as a top-tier source.

2. Sun Pharmaceutical Industries Ltd. (India)

   • A leading Indian pharmaceutical giant with extensive API manufacturing capabilities.
   • Offers tapentadol API primarily for domestic and export markets; their facilities are USFDA and EMA approved.
   • Strategic advantages include cost competitiveness and a robust supply chain.

3. Granules India (India)

   • Known for API manufacturing across a range of therapeutic classes, including opioids like tapentadol.
   • Maintains cGMP compliance with certifications from major regulatory agencies.
   • Has established supply agreements with multiple U.S.-based pharmaceutical companies.

4. DAIICHI SANKYO CO., LTD. (Japan)

   • Part of the Daiichi Sankyo group, specializing in pharmaceuticals and APIs with high-quality standards.
   • Their APIs adhere to global regulatory certifications, ensuring compatibility with Nucynta ER manufacturing.

5. Martin Bauer Group (Germany)

   • Global producer of specialty chemicals and pharmaceuticals, including APIs.
   • Known for strict quality standards and compliance with European and U.S. regulations.

---

Emerging Suppliers and Market Dynamics

The opioid API market has seen increased scrutiny, which constrains new entrants but also fosters high standards among existing suppliers. The landscape is dominated by long-established players, but market trends indicate potential growth in:

• Chinese API manufacturers: A significant share of global API supply originates from China, with companies like Zhejiang Hisoar Pharmaceutical Co., Ltd. and others expanding capacity. However, U.S. and European regulatory acceptance hinges on inspection outcomes and certification.

• Contract Manufacturing Organizations (CMOs): Some pharmaceutical companies outsource API production to specialized CMOs with cGMP facilities and proven compliance, such as those in India and Southeast Asia.

---

Quality Assurance and Certification

For Nucynta ER production, the API must meet or exceed regulatory standards for identity, purity, potency, and safety. Suppliers should provide Certificates of Analysis (CoA), batch documentation, and compliance reports, including:

• cGMP certification
• DEA licensing (for U.S. sources)
• ISO certifications (e.g., ISO 9001, ISO 13485)
• Data on impurity profiles and stability

Manufacturers must also ensure traceability and documentation supporting dilution, packaging, and storage.

---

Supply Chain Reliability and Risk Management

The opioids market faces supply constraints and geopolitical risks. To mitigate disruptions:

• Diversify API sourcing across multiple qualified suppliers.
• Favor suppliers with proven track records of on-time delivery.
• Evaluate supply chain transparency, including raw material sourcing and logistics capabilities.
• Establish contractual agreements with contingency provisions for emergency procurement.

---

Pricing Dynamics

API prices are influenced by raw material costs, regulatory compliance expenses, and geopolitical factors. High-quality, compliant API sources typically command premium prices but justify cost through regulatory assurance and supply stability.

Indian and Chinese manufacturers tend to offer competitive pricing, but often require additional validation and audits to meet the standards of North American regulators.

---

Regulatory and Market Trends

Innovations in API synthesis, such as greener and more efficient processes, are increasingly valued. Nevertheless, the opioid crisis has prompted stricter oversight, influencing supplier selection and downstream manufacturing practices. The emphasis remains on qualified suppliers with compliance histories.

---

Conclusion

Securing a reliable, compliant bulk API source for Nucynta ER's active ingredient, tapentadol, necessitates a comprehensive evaluation of prospective suppliers' regulatory certifications, manufacturing capabilities, quality assurance measures, and supply stability. Leading manufacturers include Mitsubishi Tanabe Pharma, Sun Pharma, and Granules India, with additional consideration given to emerging markets and CMOs. Ongoing monitoring of market trends, regulatory developments, and geopolitical risks is essential for maintaining an uninterrupted supply chain.

---

Key Takeaways

• Regulatory compliance is paramount: Ensure API suppliers hold current cGMP, DEA licenses, and applicable certifications (ISO, USFDA, EMA).
• Choose reputable, established manufacturers: Top-tier suppliers like Mitsubishi Tanabe, Sun Pharma, and Granules India provide high-quality APIs suitable for Nucynta ER production.
• Diversify sourcing to mitigate risks: Relying on multiple qualified suppliers enhances resilience to supply disruptions.
• Prioritize quality assurance: Regular audits, Certificates of Analysis, and traceability are non-negotiable.
• Monitor market trends continuously: Regulatory reforms, geopolitical shifts, and new synthesis technologies influence API sourcing strategies.

---

FAQs

1. What are the main challenges in sourcing API for Nucynta ER?
   Supply chain disruptions, regulatory compliance, and maintaining consistent quality are primary challenges, especially given the strict controls over opioids.

2. Are Chinese API manufacturers suitable for producing tapentadol?
   While Chinese manufacturers can supply tapentadol at competitive prices, manufacturers must demonstrate compliance with U.S. and EU quality standards through certificates and inspections.

3. How does regulatory compliance impact API sourcing decisions?
   Regulatory compliance ensures the API can be legally used in pharmaceutical products across target markets and avoids potential delays or recalls.

4. What factors influence API pricing for Nucynta ER?
   Raw material costs, manufacturing complexity, regulatory overhead, geopolitical factors, and supplier reputation influence pricing.

5. Can newer suppliers enter the tapentadol API market successfully?
   Yes, but they must meet strict regulatory standards, demonstrate high-quality manufacturing capabilities, and establish supply reliability to compete effectively.

---

References

[1] U.S. Food and Drug Administration (FDA). “cGMP Compliance: Fundamentals & Technical Guidance.” FDA, 2022.
[2] European Medicines Agency (EMA). “Quality Standards for APIs.” EMA, 2022.
[3] Pharmaceutical Technology. “Global API Market Trends.” Pharma Tech, 2022.
[4] MarketWatch. “Opioid API Market Overview.” MarketWatch, 2022.
[5] Industry Reports. “Global API Supply Chain and Risk Analysis,” 2022.